Next Phase Newsletter

The company, headquartered in California, is a multinational healthcare technology company which develops, manufactures, and sells solutions to support the vision of a fully autonomous pharmacy. The company is focused on transforming the pharmacy care delivery model and executing on the vision of the autonomous pharmacy by delivering automation, intelligence, and advanced services, powered by a single, cloud-based platform. The company offers medication management automation solutions and adherence tools which empower healthcare systems and pharmacies to focus on clinical care rather than administrative tasks. The company is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest. The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, research collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest.

The firm is looking for strategic partnerships with early-stage companies in the medical device and digital health sectors. The company is open to subsector and indication as it relates to the company’s core business interest. The firm is open to pre-prototype companies and will consider class 1 and 2 medical device technologies.

The firm is open to all types of management teams with technologies relating to their focus and who have an interest in a strategic partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital and growth equity firm making investments in life sciences will invest as early as Series A and through growth transactions and is currently investing out of their second fund. The firm looks to invest between $10-20M per investment. The firm is looking for companies with clinical data and/or commercial products. The firm has a preference for funding companies that are repurposing existing approved technologies for new indications. The firm is willing to invest in therapeutics, medical device and diagnostics companies.

The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication.

The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 is focused on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. Currently, the firm is partnered with the Chinese Government to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also interested in medical devices focusing on large disease areas within China such as diabetes and cancer. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where the firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Western Europe closed their first fund in 2012 and the portfolio companies have advanced into clinical stages, raised additional funding and one of the companies has recently completed an exit. The firm recently raised a second fund for Pre-Seed, Seed, and Series A investments with a focus in technology transfer in all four life science sectors. The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept, and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is also looking to expand this network into the US as well. The firm is looking for investments across Europe.

The firm invests in all four life science sectors, but has a particular focus on therapeutics. Within therapeutics the firm has an interest in cutting edge technologies in advanced therapies, gene and cell therapy, gene editing and synthetic biology. The firm is agnostic to subsector and indication and will invest in pre-clinical companies and follow the companies through the development of the project with additional investors. The firm is open to all 3 classes of medical devices.

The firm looks for companies with a scientific founder, and preferably a C Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. The firm will co-invest in medtech investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund based in USA for their first fund and will invest from early to later stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $10M or more, but may participate in earlier rounds, primarily as a fund of funds. The firm will invest globally, and prefers companies developing platform technologies or with multiple assets.

Within therapeutics, the firm is interested in small molecules, biologics and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases. The firm is willing to invest from pre-IND all the way to PIPEs.

The firm is willing to lead or co-invest, but is a very active investor, and will take at least one board seat after investment. As an individual investor, the firm prefers to invest at least $10M per company, but may invest in smaller rounds as an LP of another investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Life Science focused private equity and venture capital firm based in Asia is also the co-manager of another life sciences focused fund. The firm is an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.